Tricor is a drug owned by Abbvie that was authorized for market use on 05 November, 2004. This medication, which is available in tablet form for oral administration, contains the active ingredient fenofibrate. Abbvie holds two patents for Tricor.
The patent for Tricor expired on February 21, 2023, making the release of Tricor generic possible after that date. This expiry date is related to two patents held by Abbvie, US7320802 titled 'Methods of treatment using nanoparticulate fenofibrate compositions' and US7276249 titled 'Nanoparticulate fibrate formulations'
Tricor is utilised as an adjunctive therapy to diet in adults. It is formulated to reduce LDL-C, triglycerides and Apo B, while increasing HDL-C in patients suffering from primary hypercholesterolemia or mixed dyslipidemia. Furthermore, Tricor is effective in treating hypertriglyceridemia.
Two patents related to Tricor have expired. The last patent, titled 'Methods of treatment using nanoparticulate fenofibrate compositions' came under the patent number US7320802 and expired on February 21, 2023. The Tricor generic could potentially be released thereafter. Below are the details of the patent: